SARS-CoV-2 non-structural protein 13 (NSP13) (NSP13)

SARS-CoV-2 non-structural protein 13 (NSP13) is a multi-functional enzyme that plays a critical role in the viral replication and transcription process (UniProt P0DTD1). It is a member of the Superfamily 1 (SF1) helicases and is characterized by its ability to unwind double-stranded RNA or DNA in a 5'-to-3' direction using the energy derived from ATP hydrolysis (Jia et al., 2021). Beyond its helicase activity, NSP13 also functions as an NTPase and an RNA 5'-triphosphatase, the latter being essential for the initial step of viral mRNA capping (Newman et al., 2021). This capping process protects viral RNA from host cell degradation and immune detection, facilitating efficient viral protein synthesis. NSP13 forms a stable complex with the RNA-dependent RNA polymerase (NSP12) and other non-structural proteins to constitute the replication-transcription complex (RTC), where it significantly enhances the efficiency of RNA synthesis (Shu et al., 2020). Because NSP13 is one of the most highly conserved proteins among coronaviruses, it is a prime target for the development of broad-spectrum antiviral therapies aimed at treating COVID-19. Experimental inhibitors such as bismuth-based compounds and various small molecules like SSYA10-001 are currently being investigated for their ability to disrupt NSP13's enzymatic functions and halt viral replication (Yuan et al., 2020). Targeting NSP13 offers a strategic advantage due to its low mutation rate compared to other viral proteins, potentially reducing the likelihood of drug resistance.

Other names

HelicaseNSP13 helicaseSARS-CoV-2 RNA helicaseNTPase/helicaseReplicase polyprotein 1ab (NSP13)

Inhibition of the ATP-dependent 5'-to-3' RNA unwinding activity and/or the associated NTPase activity, thereby disrupting the viral replication-transcription complex (Jia et al., 2021).